WIT LLC’s Verve Therapeutics VERV Stock Holding History

WIT LLC’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14	Closed	-$472	–	13
2022 Q3	$472	Buy	+14	New	+$447	0.01%	13

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

WIT LLC's VERV Position: Q4 2022 in Review

WIT LLC sold out of Verve Therapeutics (VERV) in Q4 2022, closing a stake of 14 shares — an estimated $472 sold.

WIT LLC first reported a position in VERV in Q3 2022 and held it in 1 quarter. The position peaked at $472 in Q3 2022. 123 funds tracked by Wall St. Rank hold VERV as of Q4 2022.

WIT LLC reported no remaining Verve Therapeutics position as of Q4 2022 after selling out during the quarter.
WIT LLC sold 14 Verve Therapeutics shares in Q4 2022, an estimated $472.
WIT LLC first reported a position in Verve Therapeutics in Q3 2022 and held it in 1 quarter.
WIT LLC's Verve Therapeutics position peaked at $472 in Q3 2022.
123 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2022.

Based on WIT LLC's 13F filing for Q4 2022, filed 14 Feb 2023.